22 results about "Botulinum toxin type C" patented technology

The present disclosure relates to methods of producing a 900 kDa BoNT / A complex, wherein the method does not comprise a step of precipitation during the purification process. Further provided herein are methods of preparing a Clostridium botulinum working cell bank (WCB).

The present application relates to methods of treating or preventing infection-related immune conditions using compositions comprising IgM. In particular, the present application provides a method for treating immune complications resulting from infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. In some embodiments, the treatment of immune complications is carried out by immunomodulation. Also provided is a method for immunomodulating an infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. The present application also provides a composition comprising IgM for use in the treatment of sepsis and a composition comprising IgM for use in the treatment of immune complications resulting from infection. In some embodiments, the above-mentioned infection or sepsis results from E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Clostridium difficile, Clostridium botulinum, or a combination thereof.

The present invention relates to a culture medium composition for producing botulinum toxin, and more particularly, to a culture medium composition for culturing Clostridium species capable of producing botulinum toxin. The culture medium composition of the present invention comprises casein hydrolysate and at least one plant-derived proteose peptone selected from the group consisting of pea hydrolysate, cottonseed hydrolysate, and wheat gluten hydrolysate. When Clostridium botulinum is cultured using the culture medium according to the present invention containing plant-derived proteose peptone, casein hydrolysate, and minerals, the growth rate of the bacteria in the culture medium is higher than that in each of the currently used culture medium and the culture medium containing only plant-derived proteose peptone. In addition, when the culture medium of the present invention is used, it is possible to produce a high concentration of botulinum toxin by culturing the bacteria in a safe manner.

Disclosed are a medium composition for culturing Clostridium botulinum comprising a potato peptone, a yeast extract and glucose, and a method of preparing a botulinum toxin using the same. The medium excludes animal-derived products and major allergens, and enables the botulinum toxin-producing strain to reach the maximum growth level within a short time, thereby providing effects of shortening the production time and reducing the production cost in the botulinum toxin production process.

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A), human serum albumin (HSA) and sodium chloride (NaCl); wherein less than 34% of soluble HSA conta

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) and human serum albumin (HSA), wherein the solid compositions comprise a low amount of HSA aggregates. Further provided herein are methods of producing solid compositions comprising BoNT / A and HSA by drying a solution comprising BoNT / A in a manner such that the solution does not undergo freezing during drying.

The present invention relates to a method of purifying a non-toxic protein-removed Clostridium botulinum neurotoxin protein.

A composition comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a plurality of variant species, wherein the variant species comprises BoNT / A with a C-terminal trunca

The present invention relates to a culture medium composition for producing botulinum toxin, and more particularly to a culture medium composition for culturing Clostridium sp. strains capable of producing botulinum toxin. When a Clostridium botulinum strain is cultured using a culture medium comprising vegetable peptone, glucose, and yeast extract without animal-derived components, the growth rate of the strain is increased compared to existing culture media, and the strain can be safely cultured since animal-derived components are not included, thereby increasing the yield of botulinum toxin.

The invention relates to the technical field of food microorganisms, in particular to a long-acting slow-release antibacterial preparation targeting clostridium botulinum spores as well as a preparation method and application of the long-acting slow-release antibacterial preparation. The long-acting slow-release bacteriostatic preparation comprises a wall material and a core material, the core material comprises a lactic acid bacteria metabolite and a spore coating penetrant; the wall material is prepared from konjac glucomannan, tannic acid, polylysine salt and hyaluronic acid. By preparing a core material compound and embedding the core material compound in a wall material microcapsule, a three-layer action system of spore coating damage, skin layer degradation and core metabolism inhibition is constructed. The preparation can significantly improve the targeting and stability of antibacterial components, realizes complete substitution of nitrite in meat products, has the characteristics of safety, high efficiency and long acting, and conforms to the national food safety and health industrial policy.

Provided herein are compositions comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a 150 kDa BoNT / A. Said 150 kDa BoNT / A is in the form of a plurality of sequence variant species, wherein the plurality of sequence variant species comprises a 150 kDa BoNT / A sequence variant species with a C-terminal truncated light chain.

The present invention relates to the technical field of a method for preparing a recombinant botulinum toxin type A, and particularly relates to a botulinum toxin type A obtained by means of gene recombination technology, the amino acid sequence of which is identical to the sequence of botulinum toxin type A prepared by means of extraction and purification from a wild Clostridium botulinum strain. Provided is a single-chain protein of botulinum toxin type A, sequentially comprising: a light chain of botulinum toxin type A or a modified light chain of botulinum toxin type A, a linking region, and a heavy chain of botulinum toxin type A. The single-chain protein is subjected to fermentation, crude purification, enzyme digestion, and fine purification to obtain high-quality recombinant botulinum toxin type A. The present invention can solve the existing problems of complex process, long period, high safety risk and the like in the preparation of botulinum toxin type A by using wild Clostridium botulinum strains, and also solve the existing problem that the amino acid sequence of botulinum toxin type A prepared by means of gene recombination technology cannot be identical to that of botulinum toxin type A prepared by wild Clostridium botulinum strains.

The present invention relates to a method for purifying Clostridium botulinum toxin, comprising separating a non-toxin protein and an uncomplexed botulinum toxin protein, and performing a purification process of hydrophobic interaction and ion-exchange chromatography, thereby obtaining the uncomplexed botulinum toxin protein having high purity and increased yield. By using the botulinum purification method of the present invention, various industrial uses are possible and, in particular, botulinum toxin, which is in high demand in the pharmaceutical field, can be economically and highly-efficiently mass-produced, and thus can be effectively used in the industry.

The utility model discloses a filtering and sterilizing device for botulinum toxin, which relates to the technical field of botulinum toxin sterilizing and filtering and comprises a storage bottle, a liquid pump, a pressure valve, a membrane filter, a breaker, two liquid stopping clamps, three hoses and a collecting bottle. The three hoses are respectively a hose I, a hose II and a hose III, the hose I is connected between the output end of the storage bottle and the input end of the liquid pump, the hose II is connected between the output end of the liquid pump and the input end of the membrane filter, and the hose III is connected between the output end of the membrane filter and the input end of the collection bottle. In the process of filtering the botulinum toxin solution, the botulinum toxin solution can be in a closed environment in the whole process, and the risk that clostridium botulinum aerosol in the air pollutes the filtered solution in the thallus separation process can be effectively avoided, so that the condition that viable bacteria in the process of the section enter the process of the next section is effectively prevented, and the quality of the botulinum toxin solution is improved. The biological safety risk is reduced.

The invention provides a nano antibody for resisting a C-type botulinum toxin receptor binding domain and application of the nano antibody. The C-type botulinum toxin receptor binding domain is used as an antibody to immunize alpaca, RNA is extracted from mononuclear cells of the alpaca, and the nano antibody resisting the C-type botulinum toxin receptor binding domain is screened from the mononuclear cells by using a phage display library technology. The nano antibody provided by the invention can be specifically bound with a C-type botulinum toxin receptor binding domain, has high affinity, can effectively inhibit specific binding of C-type botulinum toxin and a target cell membrane, and can neutralize the C-type botulinum toxin to play a protective role. The nano antibody provided by the invention is expected to be applied to preparation of C-type botulinum toxin poisoning antidotes. Meanwhile, the nano antibody provided by the invention can be applied to qualitative and quantitative analysis and detection of C-type botulinum toxin as a capture antibody and a detection antibody.

The present disclosure relates to methods for preparing Clostridium botulinum working cell bank. Further provided herein are methods of producing a composition comprising a 900 kDa BoNT / A complex, said method comprising an acid precipitation step.

The present application relates to the preparation method of type A recombinant botulinum toxin technical field, specifically relates to the type A botulinum toxin obtained by gene recombination technology, the amino acid sequence is identical with the sequence of type A botulinum toxin prepared by wild strain Clostridium botulinum extraction and purification.The technical scheme provides a single chain protein of type A botulinum toxin, which comprises in sequence: type A botulinum toxin light chain or modified type A botulinum toxin light chain, connecting region, type A botulinum toxin heavy chain.The single chain protein of the scheme is obtained after fermentation, crude purification, enzyme cutting and fine purification High-quality recombinant type A botulinum toxin.The technical scheme can solve the problems of complex process, long cycle, high safety risk and the like of the existing type A botulinum toxin prepared by wild strain Clostridium botulinum, and solve the problem that the existing gene recombination technology cannot obtain the amino acid sequence identical with the type A botulinum toxin prepared by wild strain Clostridium botulinum.

The present invention relates to a culture medium composition for producing botulinum toxin, and more particularly, to a culture medium composition for culturing Clostridium species capable of producing botulinum toxin. The culture medium composition of the present invention comprises at least one plant-derived proteose peptone selected from the group consisting of pea hydrolysate, cottonseed hydrolysate, and gluten hydrolysate. When Clostridium botulinum is cultured using the culture medium according to the present invention containing plant-derived proteose peptone and minerals, the growth rate of the bacteria in the culture medium is about 1.5-2 times higher than that of the bacteria in the currently used culture medium. In addition, when botulinum toxin is produced by culturing the bacteria in the culture medium, infection of transmissible spongiform encephalopathy (TSE) and the like is prevented by blocking the introduction of animal-derived components.

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) and human serum albumin (HSA), wherein the solid compositions comprise a small amount of HSA aggregates. Further provided herein are methods for preparing solid compositions comprising BoNT / A and HSA by drying a BoNT / A-containing solution such that the solution does not freeze during drying.

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) and human serum albumin (HSA), wherein the solid compositions comprise a low amount of HSA aggregates. Further provided herein are methods of producing solid compositions comprising BoNT / A and HSA by drying a solution comprising BoNT / A in a manner such that the solution does not undergo freezing during drying.

The invention discloses a clostridium botulinum neurotoxin A receptor binding structural domain mutant with high affinity, and compared with a wild type clostridium botulinum neurotoxin A receptor binding structural domain, the clostridium botulinum neurotoxin A receptor binding structural domain mutant has any one of the following amino acid mutation sites: P1139S, L1154A, G1157L, R1140H, I1148N, L1154G, L1154Y, S1153G and Y1165W. The affinity of the botulinum neurotoxin A receptor binding domain mutant and a receptor SV2 is remarkably higher than that of a wild type, and the mutant and recombinant protein have wide application prospects in the fields of drug delivery, neurological disease treatment, biological detection and the like.

The present invention relates to solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A) and human serum albumin (HSA), wherein the solid compositions comprise a small amount of HSA aggregates. The present invention further relates to methods of producing solid compositions comprising BoNT / A and HSA by drying a solution comprising BoNT / A such that the solution does not undergo freezing upon drying. Figure for abstract: 2A